Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50
Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50
Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL (“Coris”) to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million
Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that it has raised gross proceeds of £3.25 million from long term, high net worth
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Outlining Progress Against Strategic Objectives
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
Preliminary Results for the Year Ended December 31, 2024
Update on timing of preliminary results announcement
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for